Pharmaceutical Investing CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual Meeting
Pharmaceutical Investing CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
Pharmaceutical Investing CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
Resource Expansion Drilling Confirms 3,000 metres of New Uranium Trends with Best Drill Hole of 1.4 GT over 7.6 metres
